Melanoma Clinical Trials
CPMC Cancer ServicesOpens new window
Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page
Further protocol information can be found on the links below at ClinicalTrials.gov
Active Trials
Title: Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Description: Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Investigator: David Minor, MD
Eligibility: Subjects who have advanced stage III melanoma
Status: Active and open to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study BMS 184-029
Title: A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Description: Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma
Investigator: David Minor, MD
Eligibility: Previously Treated Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease
Status: Active and open to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study Biovex 005-05
Title: An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Description: To assess the objective response rate of E7080 in previously treated subjects with unresectable stage III or stage IV melanoma and disease progression
Investigator: David Minor, MD
Eligibility: 18 Years and older with unresectable Stage III or Stage IV melanoma
Status: Active and open to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study Eisai 7080-206
Title: A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Description: A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Investigator: David Minor, MD
Eligibility: 18 Years and older with advanced (unresectable Stage III) or metastatic (Stage IV) melanoma that is BRAF mutation positive (V600E)
Status: Active and open to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study GSK BRF113683
Title: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Description: A Study of GSK2118436 in BRAF Mutatant Metastatic Melanoma to the Brain
Investigator: David Minor, MD
Eligibility: 18 Years and older with BRAF mutation-positive metastatic melanoma to the brain
Status: Active and open to enrollment
Contact: Laurel Fiske, 415-600-1654,
Email: FiskeL@cpmcri.org about Study GSK BRF113929
Title: A Phase II Study of Sunitinib Therapy for Patients with Metastatic Melanoma and KIT Gene Aberrations (Sutent-Kit)
Description: To determine the response rate of metastatic melanoma patients with KIT aberrations to therapy with sunitinib using RECIST criteria
Investigator: David Minor, MD
Eligibility: Subjects with Metastatic Melanoma and KIT Gene Aberrations
Status: Active but closed to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study Sutent-Kit
Title: A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab in Subjects With Unresectable Stage III or IV Melanoma
Description: Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Investigator: David Minor, MD
Eligibility: Subjects who have advanced stage III or IV melanoma that cannot be treated with surgery
Status: Active but closed to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study BMS 184-045
Title: A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols
Description: A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
Investigator: David Minor, MD
Eligibility: Subjects who have advanced melanoma and have received a drug called ipilimumab in an earlier study
Status: Active but closed to enrollment
Contact: Ron Frianeza, 415-600-3027,
Email: FrianeR@cpmcri.org about Study BMS 184-025
- updated May 2011
Back to top